COVID-19 VACCINE COULD BE READY BY OCTOBER
Global pharmaceutical major Pfizer believes ...
The novel design of the trial allows for the evaluation of the various mRNA candidates simultaneously in order to identify the safest and potentially most efficacious candidate in a greater number of volunteers, in a manner that will facilitate the sharing of data with regulatory authorities in real time. “With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” Bourla said in a statement earlier this month.
“The short, less than four-month timeframe in which we've been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,” he added. In anticipation of a successful clinical development programme, Pfizer and BioNTech are working to scale up production for global supply. The breadth of this programme should allow production of millions of vaccine doses in 2020, increasing to hundreds of millions in 2021, Pfizer said.